Proellex®
On August 3, 2009, Repros Therapeutics announced it voluntarily suspended dosing of all patients in its clinical trials of Proellex. On August 4, 2009, the United States Food and Drug Administration (FDA) informed Repros that the Company's Investigational New Drug Applications (INDs) for Proellex had been placed on clinical hold for safety reasons.
Androxal®
Androxal® - Secondary Hypogonadism (ZA-201): To Evaluate Fertility in Men with Secondary Hypogonadism (AIHH*) Previously Treated with Topical Testosterone
Purpose: To determine if Androxal® can reverse the suppression of the hypothalamic-pituitary axis and secretion of pituitary hormones (LH and FSH) which stimulate testosterone production and Sertoli cell number, thereby restoring sperm count.